Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars.
Business Strategy
The company’s overarching strategy is centered around pioneering access for patients to affordable medications. This drives its commitmen…
Analysis
Middle-of-the-road
Sandoz Group AG sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
On valuation, the picture is expensive. The owner-earnings multiple stands at 39.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 15% a year, against analyst forecasts of 13%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is stretched. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202473
64
202420252026
All-time high
73
Jan 2024
All-time low
39
Jan 2025
Average rank
61
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
59
56
64
—
Price/Earnings
26
51
57
—
Price/Book
52
51
51
—
Dividend Yield
51
42
44
—
Value (overall)
49
57
43
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.